This invention relates to compounds which are generally alpha-1A/B adrenoceptor
antagonists and which are represented by Formula I:
##STR1##
wherein Z is C(O) or S(O)2, X
is carbon or nitrogen, Y is carbon, and XY considered together are two
adjoining atoms of the ring A, said ring being a fused aromatic ring of five to
six atoms per ring optionally incorporating one to two heteroatoms per ring, chosen
from N, O, or S; and the other substituents are as defined in the specification;
or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically
acceptable salts or solvates thereof. The invention further relates to pharmaceutical
compositions containing such compounds, methods for their use as therapeutic agents,
and methods of preparation thereof.
